 Isocitrate Dehydrogenase
"Isocitrate Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41.
| Descriptor ID |
D007521
|
| MeSH Number(s) |
D08.811.682.047.820.475
|
| Concept/Terms |
Isocitrate Dehydrogenase- Isocitrate Dehydrogenase
- Dehydrogenase, Isocitrate
- NAD Isocitrate Dehydrogenase
- Dehydrogenase, NAD Isocitrate
- Isocitrate Dehydrogenase, NAD
- Isocitrate Dehydrogenase (NAD+)
|
Below are MeSH descriptors whose meaning is more general than "Isocitrate Dehydrogenase".
Below are MeSH descriptors whose meaning is more specific than "Isocitrate Dehydrogenase".
This graph shows the total number of publications written about "Isocitrate Dehydrogenase" by people in this website by year, and whether "Isocitrate Dehydrogenase" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 | | 2012 | 3 | 1 | 4 | | 2015 | 4 | 0 | 4 | | 2016 | 1 | 3 | 4 | | 2017 | 3 | 0 | 3 | | 2018 | 5 | 1 | 6 | | 2019 | 2 | 2 | 4 | | 2020 | 3 | 1 | 4 | | 2021 | 2 | 1 | 3 | | 2022 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 3 | 2 | 5 | | 2025 | 4 | 2 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Isocitrate Dehydrogenase" by people in Profiles.
-
Rai M, Okah P, Shefali SA, Fitt AJ, Shen MZ, Molomjamts M, Pepin R, Nemkov T, D'Alessandro A, Tennessen JM. New alleles of D-2-hydroxyglutarate dehydrogenase enable studies of oncometabolite function in Drosophila melanogaster. G3 (Bethesda). 2025 Aug 06; 15(8).
-
Siddiq Z, Gilani A, Ung TH, Kleinschmidt-DeMasters BK. Isocitrate dehydrogenase-mutant astrocytoma in persons aged 55 years and older: Survival differences versus the young. J Neuropathol Exp Neurol. 2025 Jul 01; 84(7):611-616.
-
Tap WD, Cote GM, Burris H, Gore L, Elias A, Beeram M, Conley AP, Gianolio DA, Qu Z, Pandya S, Trent JC. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma. Clin Cancer Res. 2025 Jun 03; 31(11):2108-2114.
-
Saisuwan K, Boonnate P, Goto H, Nakagawa R, Abe M, Hirabayashi K, Fujiwara Y, Kikuta K, Okada S. Establishment and characterization of TK-DDCS1: a novel IDH1 mutated dedifferentiated chondrosarcoma cell line. Hum Cell. 2025 Jun 03; 38(4):116.
-
Fleming JL, Pugh SL, Chang SM, McElroy JP, Becker AP, Aldape KD, Shih HA, Ashby LS, Hunter GK, Bahary JP, Schultz CJ, Kavanagh BD, Puduvalli VK, Robins HI, Werner-Wasik M, Mehta M, Chakravarti A. Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma. Int J Radiat Oncol Biol Phys. 2025 Sep 01; 123(1):84-92.
-
Huang Y, Shan Y, Zhang W, Printzis C, Pesce L, Stover D, Stanhope C, Stranger BE, Huang RS. Sex differences in the molecular profile of adult diffuse glioma are shaped by IDH status and tumor microenvironment. Neuro Oncol. 2025 Feb 10; 27(2):430-444.
-
Li L, Hashemi L, Eid J, Tao W, Campoverde L, Yu A, Farooqi AA, Al-Ali H, D'Amato G, Hornicek F, Duan Z, Lohse I, Trent J. High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation. Int J Mol Sci. 2024 Dec 03; 25(23).
-
Stiff A, Fornerod M, Kain BN, Nicolet D, Kelly BJ, Miller KE, Mrózek K, Boateng I, Bollas A, Garfinkle EAR, Momoh O, Fasola FA, Olawumi HO, Mencia-Trinchant N, Kloppers JF, van Marle AC, Hu E, Wijeratne S, Wheeler G, Walker CJ, Buss J, Heyrosa A, Desai H, Laganson A, Hamp E, Abu-Shihab Y, Abaza H, Kronen P, Sen S, Johnstone ME, Quinn K, Wronowski B, Hertlein E, Miles LA, Mims AS, Oakes CC, Blachly JS, Larkin KT, Mundy-Bosse B, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Duarte C, Abbott D, Amaya ML, Jordan CT, Uy GL, Stock W, Archer KJ, Paskett ED, Guzman ML, Levine RL, Menghrajani K, Chakravarty D, Berger MF, Bottomly D, McWeeney SK, Tyner JW, Byrd JC, Salomonis N, Grimes HL, Mardis ER, Eisfeld AK. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024 Nov; 56(11):2434-2446.
-
Massaad E, Smith WJ, Bradley J, Esposito E, Gupta M, Burns E, Burns R, Velarde JK, Berglar IK, Gupta R, Martinez-Lage M, Dietrich J, Lennerz JK, Dunn GP, Jones PS, Choi BD, Kim AE, Frosch M, Barker FG, Curry WT, Carter BS, Nahed BV, Cahill DP, Shankar GM. Radical surgical resection with molecular margins is associated with improved survival in IDH wild-type glioblastoma. Neuro Oncol. 2024 Sep 05; 26(9):1660-1669.
-
Kalter JA, Yang RA, Toland A, Milla S, Lund TC, Hankinson T, Dahl NA. IDH-mutant astrocytoma arising from a demyelinating plaque in a child with X-linked adrenoleukodystrophy. J Neuropathol Exp Neurol. 2024 03 20; 83(4):289-292.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|